Introduction Nitrosamine Testing in Combination Products presents greater scientific and regulatory challenges than testing single-API drug products. When multiple APIs […]
Nitrosamine Testing in Combination Drug Products: Managing Multiple APIs Read More »
Introduction In pharmaceutical manufacturing, understanding Nitrosamine Alert Limit vs Action Limit is critical for compliance and patient safety. The distinction
Setting Alert Limits vs Action Limits for Nitrosamines: Practical Implementation Guide Read More »
Introduction: The Nitrosamine Batch Release Testing Requirement becomes mandatory when confirmatory testing shows nitrosamine impurity levels above 10% of the
Nitrosamine Batch Release Testing: When Is Routine Testing Required? Read More »
Introduction: Why Nitrosamine Testing Highly Potent APIs Requires Specialized Expertise Nitrosamine Testing Highly Potent APIs demands highly sensitive analytical methods,
Nitrosamine Testing in Controlled Substances and Highly Potent APIs (HPAPIs) Read More »
Introduction: Applying a Nitrosamine Reformulation Strategy Without Compromising Bioequivalence A structured Nitrosamine Reformulation Strategy can block nitrosamine formation pathways while
Introduction In this NDMA Root Cause Investigation Case Study, we examine a real-world scenario involving an unexpected spike of N-nitrosodimethylamine
Case Study: Root Cause Investigation of Unexpected NDMA Spike in Finished Product Read More »
Introduction Nitrosamine Testing CRO Selection requires detailed scientific evaluation and regulatory awareness. Global authorities continue to update nitrosamine guidance, and
Selecting the Right Nitrosamine Testing CRO: A Technical Due Diligence Checklist Read More »
Introduction: Why Specialized Peptide Oligonucleotide Conjugate Analysis Is Essential Peptide Oligonucleotide Conjugate Analysis is critical because peptide–oligonucleotide conjugates (POCs) combine
Analytical Testing Services for Peptide-Oligonucleotide Conjugates Read More »
Introduction: The global pharmaceutical industry is facing strict regulatory control for mutagenic impurities, especially nitrosamines. A strong understanding of NDA
NDA vs ANDA Nitrosamine Data Requirements: What Sponsors Must Submit Read More »
Introduction A comprehensive Nitrosamine Risk Assessment for ANDA Submission requires a structured and scientific evaluation of potential nitrosamine formation pathways.
How to Prepare a Complete Nitrosamine Risk Assessment Report for ANDA Submission Read More »
